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InsulinAlzheimer disease (AD) is the most common form of dementia among the elderly and is characterized by pro-
gressive loss of memory and cognition. Epidemiological data show that the incidence of AD increases with age
and doubles every 5 years after 65 years of age. From a neuropathological point of view, amyloid-β-peptide
(Aβ) leads to senile plaques, which, together with hyperphosphorylated tau-based neuroﬁbrillary tangles and
synapse loss, are the principal pathological hallmarks of AD. Aβ is associated with the formation of reactive oxy-
gen (ROS) and nitrogen (RNS) species, and induces calcium-dependent excitotoxicity, impairment of cellular res-
piration, and alteration of synaptic functions associatedwith learning andmemory. Oxidative stress was found to
be associated with type 2 diabetes mellitus (T2DM), which (i) represents another prevalent disease associated
with obesity and often aging, and (ii) is considered to be a risk factor for AD development. T2DM is characterized
by high blood glucose levels resulting from increased hepatic glucose production, impaired insulin production
and peripheral insulin resistance, which close resemble to the brain insulin resistance observed in AD patients.
Furthermore, growing evidence suggests that oxidative stress plays a pivotal role in the development of insulin
resistance and vice versa. This review article provides molecular aspects and the pharmacological approaches
from both preclinical and clinical data interpreted from the point of view of oxidative stress with the aim of
highlighting progresses in this ﬁeld.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer disease (AD) is the most common form of dementia
among the elderly and is characterized by progressive loss of memory
and cognition [1]. Epidemiological data show that the incidence of AD
increases with age and doubles every 5 years after 65 years of age
with 1275 new cases/100,000 persons/year [1,2]. TheAlzheimer Associ-
ation points out that theﬁnancial, emotional, and family costs for care of
AD patients are enormous andwill increasemarkedly in the near future
in the absence of a therapeutic modality to slow or stop onset. From a
neuropathological point of view, amyloid-β-peptide (Aβ) leads to senile
plaques, which, together with hyperphosphorylated tau-based neuroﬁ-
brillary tangles and synapse loss, are the principal pathological hall-
marks of AD. Aβ is associated with the formation of reactive oxygen
(ROS) and nitrogen (RNS) species, and induces calcium-dependent
excitotoxicity, impairment of cellular respiration, and alteration of syn-
aptic functions associated with learning and memory [1].ter of Membrane Sciences, and
y, Lexington, KY 40506-0055,Like AD, type 2 diabetes mellitus (T2DM) represents another preva-
lent disease associated with obesity and often aging, and it is estimated
that about 24 million people living in the USA show clinical symptoms
of T2DM [3]. T2DM is a condition in which high blood glucose levels re-
sult from increased hepatic glucose production, impaired insulin pro-
duction by pancreatic β-cells and “insulin resistance” [inadequate
response to insulin by target cells due to a down-regulated expression
of the insulin receptor (IR), the IGF-1 receptor (IGF-1R), and the insulin
receptor substrate (IRS) proteins] [3]. In different clinical studies, an as-
sociation of T2DMandneurodegenerative disorders aswell as decline in
memory has been described. A series of longitudinal studies has shown
that glucose intolerance and impairment of insulin secretion are associ-
ated with a higher risk to develop dementia or AD [4–6]. Indeed, it was
shown thatMCI subjects with normoglycemia at baseline had less func-
tional and global cognitive decline, less whole-brain volume loss and
lower conversion to AD than subjects with impaired glycemia over
2 year observation [7].
Vascular complicationsmight explain only partially the increased in-
cidence of neurodegeneration observed in patients with T2DM. The
causes could be an impaired β-amyloid (Aβ) clearance [8], an up-
regulation of the amyloid precursor protein (APP) expression and Aβ
deposition [9], or hyperinsulinemia, as is present in T2DM, which may
play an important role in the formation of senile plaques [10]. On the
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cosemetabolism or T2DM [11]. These observations raise questions thus
far unanswered: whether T2DM is a cause, consequence, or compensa-
tory counterregulation to neurodegeneration, andwhether neuronal in-
sulin resistance indeed represents a risk factor for AD? Alternative
mechanisms might be directly related to insulin/IGF-1 signaling, sug-
gesting a common pathogenic cerebral signaling pathway in T2DM
and neurodegeneration, including AD.
On a molecular level, several targets of the insulin machinery with
potential inﬂuence on the development of neurodegenerative disease
have been identiﬁed. Insulin and IGF-1 have intense effects in the CNS,
regulating key processes such as energy homeostasis, neuronal survival,
longevity, learning and memory [12,13]. Insulin and IGF-1 bind to the
tyrosine kinase receptors, IR, and IGF-1R, which share a high degree of
identity in their structure and function [12,13]. IR and IGF-1R are selec-
tively distributed in the brainwith a higher density in the olfactory bulb,
hypothalamus, as well as in two of the main brain areas affected by AD
pathology, i.e., hippocampus and cerebral cortex [12,13]. Binding of
insulin or IGF-1 induces a conformational change of the receptor
leading to their auto-phosphorylation on speciﬁc tyrosine residues on
the β-subunit with the consequent recruitment of the insulin receptor
substrate-1 (IRS-1) [12,13]. This latter, in turn, activates two main sig-
naling pathways: (i) the PI3K pathway, which, among other functions,
is involved in the maintenance of synaptic plasticity and memory con-
solidation [14], Aβ-induced memory loss [15], and synthesis of nitric
oxide (NO), which in turn plays a role in learning andmemory process-
es [16]; and (ii) theMAPK cascade, which is responsible both for the in-
duction of several genes required for neuronal and synapse growth,
maintenance and repair processes, as well as serving as a modulator of
hippocampal synaptic plasticity that underlies learning and memory
[3]. Importantly, neurons are vulnerable to excitotoxic stress, and with
some notable exceptions, there is a slow rate of neurogenesis in the
brain. Hence, neurons remain post-mitotic, and any increased stress or
reduced repair mechanism can accumulate over time. The impairment
of insulin signaling in the brain could well play a role in the develop-
ment of neurodegenerative disorders, as it leaves neurons more ex-
posed to toxic inﬂuences.
2. Insulin resistance: a cross-talk between AD and T2DM
Insulin resistance is clinically deﬁned as the inability of a known
quantity of exogenous or endogenous insulin to increase glucose uptake
and utilization in an individual as much as it does in a normal popula-
tion [17]. Historically, insulin was long considered to be a hormone
that primarily exerts its inﬂuence in the periphery [18]. While in the
past years, the signalingmechanism and the biological effects of insulin
have been studiedmainly in classical insulin target tissues, such as skel-
etal muscle, fat and liver, with respect to glucose uptake, regulation of
cell proliferation, gene expression and the suppression of hepatic glu-
cose production, recently, it has become clear that insulin also produces
similar effects in the central nervous system (CNS). Indeed, insulin is a
peptide secreted by pancreatic beta cells and is readily transported
into the CNS across the blood brain barrier (BBB) by a saturable,
receptor-mediated process [19,20]. Here, insulin binds to and activates
the IR (Fig. 1), that is, as cited above, widely distributed in the brain
[21–23].
In 1978, Havrankova et al. showed that insulin is present in rat brain
in high concentration, and it is independent of peripheral insulin levels
[24]. Thus, although pancreatic-derived insulin crosses the BBB and
reaches the brain, a portion of the insulin in the CNS is locally produced,
based on the detection of c-peptide (which is an integral part of the pro-
insulin molecule) and insulin mRNA in the brain [25].
Due to the well-known role of insulin in learning and memory pro-
cesses [25–27], these new lines of evidencemake the comprehension of
the mechanism(s) responsible for the observed insulin resistance in
neurodegenerative disorders more fascinating. Human postmortemstudies have convincingly shown that brain insulin resistance with re-
duced activation of receptors and downstream neuronal survival and
plasticity mechanisms are consistent and fundamental abnormalities
in AD (Fig. 1) [28–30]. Given that, and based on the concept that brain
insulin resistance shows a series of similarities with the peripheral insu-
lin resistance, AD was described as a form of T2DM commonly called
type 3 diabetes [31,32]. Notwithstanding, as recently reported by Talbot
andWang, the concept of type 3 diabetes is no longer correct for a cou-
ple of reasons including the fact that: (a) hyperglycemia –which is the
key diagnostic features of diabetes – is not present in AD CSF: and (b) it
is not clearly demonstrated that AD brain is insulin-deﬁcient [33].
Thus, insulin resistance represents the main feature linking T2DM
and the risk to develop AD. Indeed, from a pathological point of view,
the early stages of T2DM are characterized by hyperinsulinemia (the
pancreas makes extra insulin) and insulin resistance (reduced insulin
efﬁciency); however, hepatic glucose production remains normal,
with fasting euglycemia and postprandial hyperglycemia relatively
mild. In the later stages of T2DM, insulin resistance persists, hepatic
glucose production rises, and endogenous insulin production falls,
resulting in fasting and postprandial hyperglycemia [34]. While acute
hyperinsulinemia may produce beneﬁcial effects on cognition, persis-
tently high levels of circulating insulin (as observed in the ﬁrst phase
of T2DM) may conversely exert a negative inﬂuence on memory and
other cognitive functions. Indeed, raisingperipheral insulin levels acute-
ly elevates brain and cerebrospinal ﬂuid insulin levels, whereas
prolonged peripheral hyperinsulinemia down-regulates insulin recep-
tors at the BBB and reduces insulin transport into the brain (Fig. 1)
[35,36]. In that regard, patients withmoderate-to-severe AD showed el-
evated true plasma insulin levels, related to healthy older adults, thus
suggesting the insulin resistance as a risk factor in AD pathology [34].
Based on both pre-clinical and clinical lines of evidence, it is broadly
accepted that AD pathology is driven/worsened by the appearance of
the insulin resistance, how brain insulin/IGF-1 resistance and deﬁciency
develop is not completely understood [37].
3. Oxidative stress: is it the driving force for insulin resistance in AD?
Reactive oxygen species/reactive nitrogen species (ROS/RNS) play a
dual biological role in living systems since they can be either beneﬁcial
or detrimental [38]. Low levels of ROS exert beneﬁcial physiological
roles in cellular responses to stress and in the activation of several cellu-
lar signaling pathways, such as synaptic signaling, where ROS are mes-
senger molecules in long-term potentiation (LTP) [39,40]. Moreover,
moderate ROS levels are thought to improve peripheral insulin sensitiv-
ity [41]. On the other hand, imbalance between the production of ROS/
RNS as a consequence of mitochondrial dysfunction and the intracellu-
lar antioxidant capacity leads to abnormally elevated ROS levels and a
condition known as oxidative stress (OS) that is followed by oxidative
damage to cells and, eventually, death (Fig. 1) [42]. Increased OS has
been implicated in the pathology of several diseases and the accumula-
tion of oxidatively damaged proteins, lipids, and nucleic acids correlates
with the onset of age-related cellular alterations, especially in diabetes
and AD [43,44]. Indeed, OS represents a central pathophysiological me-
diator of diabetes and is deeply involved into the development and pro-
gression of neurodegenerative diseases [45]. Due to its elevated levels of
peroxidable fatty acids, high requirement for oxygen, relative paucity of
antioxidant systems, and richness in iron content, the brain is extremely
sensitive to OS [42,46]. Therefore, neurons are particularly susceptible
to oxidative damage and aging, together with age-related diseases, con-
tributes to the disruption of the balance between ROS generation and
antioxidant defense resulting in the damage of fundamental biological
macromolecules [47].
Oxidative damage to lipids and protein of neuronal membrane af-
fects activities of membrane-bound enzymes, ion channels and recep-
tors. ROS/RNS attack biological component of the cell resulting in the
formation of stable adducts with DNA and RNA and can damage cell
Fig. 1. Increased oxidative stress levels as a central event driving insulin resistance inAlzheimer disease brain. Persistently high levels of circulating insulin (as observed in theﬁrst phase of
T2DM)may exert a negative inﬂuence onmemory and other cognitive functions by down regulation of insulin receptors (IR) at the blood brain barrier and consequently reduced insulin
transport into the brain (as observed in AD), thus leading to insulin resistance. From amolecular point of view, the lack of interaction between insulin and IR is associatedwith an increase
of the inhibitory phosphorylation on insulin receptor substrate-1/2 (IRS1/2) on Ser312, 616 and636,which, in turn, negatively impacts on the twomain arms of insulin-mediated signaling
cascade: the PI3K and the MAPK pathways, both involved in the maintenance of synaptic plasticity and cell stress response. Furthermore, turning off insulin signaling results in impaired
glucose transport (reduced translocation of the glucose transporter at the plasmamembrane) andmetabolism thus promoting an alteration ofmitochondrial processes involved in energy
production. In turn, impairment of mitochondria functions leads to a vicious circle in which reduced energy production is associated with an increase of ROS and RNS responsible for the
oxidative/nitrosative damage ofmitochondria aswell as other cellular components. In addition, increased Aβ production and accumulation,which represent key features of ADpathology,
also promote mitochondrial impairment. Moreover, insulin resistance-associated impairments in glucose uptake and utilization are associated with increased endoplasmic reticulum
(ER) stress, which deregulate lipid metabolism, causing accumulation of toxic lipids in the brain. All these events contribute to the increased oxidative stress levels responsible of
neurodegeneration observed in AD brain. Although insulin resistance and Aβ production can be considered leading causes of the rise of oxidative stress, this latter, in turn, promotes
IRS-1/2 Ser-312, -616 and -636 phosphorylation aswell as the oxidative damage of protein involved in glycolysis, the Krebs cycle and ATP synthesis that are crucial events in the reduction
of glucosemetabolism and thus insulin resistance. Finally, because insulin resistance is associated with increased Aβ production and Aβ production is postulated to be responsible for the
onset of insulin resistance, it remains to be clariﬁed whether insulin resistance is a cause, consequence, or compensatory response to Aβ-induced neurodegeneration.
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reacting with metals, nitrogen or carbon to form intermediates that
react with proteins (e.g., through nitration, carbonylation, nitrosylation
or reactive alkenals by Michael addition) [48,49]. Oxidation of amino
acids can lead to the formation of advanced glycation end products
(AGEs), advanced oxidation protein products (AOPPs), peroxides and
carbonyls that can attack other molecules and generate radicals
resulting in protein unfolding and in rendering the protein inactive
and prone to aggregation [50].
The idea of OS as a link between T2DM and AD is currently under
evaluation by several research groups. Both T2DM and AD have
common pathogenic factors, and evidence suggests a close link for the
presence of cellular OS, mitochondrial abnormalities and paucity in an-
tioxidant defenses [51–53]. Since mitochondria are the central coordi-
nators of energy metabolism and are sources and targets of ROS, their
impairment may represent a downstream event of T2DM and/or AD-
associated abnormal brain insulin and glucose metabolism [38,54].
Indeed, it has been shown that increased OS leads to the inhibition of
cellular energy production and to the reduction of both insulin secretionand sensitivity [55,56]. In turn, defective insulin signaling makes neu-
rons energy-deﬁcient and more vulnerable to oxidizing insults, which
could promote structural and functional alterations of mitochondria
(Fig. 1) [51,57].
OS is also believed tomodify a number of signaling pathways related
to protein unfolding response and protein degradation that can ulti-
mately lead to insulin resistance [58]. In T2DM individuals, resistance
to insulin signaling beyond the increase of OS makes neurons energeti-
cally defective and susceptible to oxidizing or other metabolic insults
impairing synaptic plasticity [59]. Moreover, insulin resistance-
associated impairments in glucose uptake and utilization are associated
with increased ER stress, which, deregulate lipid metabolism, causing
accumulation of toxic lipids in the brain [60]. Moreover, in T2DM sub-
jects the increased production of ROS, as a consequence of elevated glu-
cose levels can be reduced with the administration of antioxidants [58].
Increasing data support the idea that aging-related alterations of mito-
chondrial function represent the driving force of increased OS in
T2DM contributing to the progression and development of AD patholo-
gy [51,55,56,60–62].
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that mitochondrial failure may represent a functional link between
both pathologies. A study on a rat model of sporadic AD generated by
the intracerebroventricular (icv) injection of a sub-diabetogenic dose
of streptozotocin (STZ) demonstrated that the insulin-resistant brain
state is accompanied by the occurrence of mitochondrial abnormalities
[63], while STZ-induced T1DM rats showed no signiﬁcant changes in
mitochondrial function and synaptic integrity as result of compensation
mechanisms, although reverted by insulin administration [64]. The
comparison 3xTg-AD mice with sucrose-treated WT mice reported by
Carvalho and colleagues [65] showed a similar impairment of mito-
chondrial respiratory chain and phosphorylation system, as well as ox-
idative imbalance and increased Aβ levels, consistent with the notion
that mitochondrial metabolic alterations associated with diabetes con-
tribute to the development of AD-like pathologic features. In agreement
with this notion, comparison of 11-month-old T2D and AD mice
showed, in addition to increased Aβ levels, similar behavioral and cog-
nitive anomalies characterized by increased fear and anxiety and de-
creased learning and memory abilities [66]. In addition, diabetic and
non-diabetic rats infused with Aβ had both profound decreased energy
intake, activity and fat oxidation and increased carbohydrate oxidation
and energy expenditure; however, these effects were aggravated by
10% to 20% in the diabetic rat group [67].
In a recent study on microvascular endothelial cells from rat
(RBMEC) and mice (MBMEC) isolated from adult Sprague–Dawley
rats and homozygous db/db (Leprdb/Leprdb) and heterozygous
(Dock7m/Leprdb) mice, respectively, and cultured under normal- or hy-
perglycemic conditions for 7 d followed by 24 h exposure to Aβ(1–40)
showed that high glucose levels increase the susceptibility of brain
microvascular endothelial cells to Aβ toxicity, supporting the idea that
hyperglycemia is a major risk factor for vascular injury associated with
AD [68].
In addition to Aβ pathology, insulin reportedly could regulate Tau
phosphorylation in neuronal cells [69,70], which was conﬁrmed by ob-
servations of hyperphosphorylated Tau inmice showing abnormal insu-
lin levels in the brain [71,72]. Among the kinases able to phosphorylate
Tau in vitro, GSK-3β is considered to be one of the major physiological
and pathological Tau kinases [73]. However, studies that have addressed
GSK-3β activation in diabetic animal models have reported conﬂicting
results [74]. It was recently demonstrated that tau overexpression was
inﬂuenced by a high fat independently of peripheral hyperglycemia,
hyperinsulinemia or insulin resistance in brains of wild-type mice and
in mouse models of T2DM and AD [75].
Patientswith AD pathology demonstrated the concomitant presence
of mitochondrial bioenergetics failure, increased OS and reduced
insulin signaling as consequence of increased Aβ and levels of
hyperphosphorylated tau (Fig. 1) [52,53]. In brains of subjects with
AD, deﬁcits in insulin signaling are due to both insulin deﬁciency and in-
sulin resistance that aremanifested by reduced levels of insulin receptor
binding and decreased responsiveness to insulin stimulation (Fig. 1)
[29,76]. Hence, AD is considered a brain form of diabetes with features
of both insulin resistance and insulin deﬁciency. The progressive
worsening of insulin resistance along stages of AD correlates with the
increased OS, DNA damage and protein oxidation demonstrated by 4-
hydroxynonenal (HNE), protein carbonyls (PCO) and 3-nitrotyrosine
(3NT) accumulation [51]. It wasproposed that insulin resistance togeth-
er with decreased brain insulin levels might lead to accumulation of Aβ
and consequently AD (Fig. 1) [77]. In addition, insulin administration
modulates the cellular clearance of Aβ [78] and reduces Aβ-induced
OS, exerting a protective effect on synapses from AD-related damage
[79–81].
Themechanism of protection by insulin appears to involve the resto-
ration of the Akt/mTOR/S6K signaling pathway within AD neurons that
when aberrantly modulated may increase IRS-1 phosphorylation at
Ser312, resulting in IRS-1/2 degradation, thus impairing IR-associated
neurotropic and metabolic brain functions [38,82–84]. A mechanisminvolving anomalous calcium inﬂux and OS may underlie insulin resis-
tance in AD since chelation of intracellular calcium with BAPTA-AM
prevents both oligomer-induced insulin inhibition and OS [41,85].
Moreover, the presence of a NMDA-R blocker (memantine) attenuated
the Aβ oligomer-induced increase in intraneuronal calcium essential in
causing neuronal OS; thus, NMDA-R dysfunctionmight play a role in OS
and defective neuronal insulin signaling in AD [86,87]. These studies
suggest a possible physiological feedback between neuronal activity
and insulin signaling.
Elevated levels of AGE represent another common pathological
marker of both T2DMand AD. Clinical studies have shown that elevated
blood glucose levels result in signiﬁcantly increased accumulation of
AGEs in tissues of diabetic subjects [88]. Diabetic patients could have
an increased risk of AD via AGE production since the modiﬁcation of
Aβ by AGE accelerates Aβ aggregation and the glycation of tau stabilizes
neuroﬁbrillary tangles [52]. High levels of AGE immunoreactivity are
present in AD plaques and neuroﬁbrillary tangles [89–92]. Moreover,
RAGE has been found to be a receptor for Aβ and mediates Aβ induced
microglia activation and subsequent inﬂammation in AD [93,94].
3.1. Protein oxidation vs. antioxidant system in T2DM and AD
3.1.1. Protein oxidation
As noted above reduced glucose metabolism occurs both in T2DM
and AD and increases the production of free radicals such as ROS/RNS
as consequence of mitochondrial failure. In turn, the increased produc-
tion of ROS/RNS results in protein oxidation and/or lipid peroxidation
that contributes to further mitochondrial damage and decreased ATP
production (Fig. 1). Increased oxidation, including protein bound-HNE,
protein carbonyls, and protein resident-3NT, in metabolic-related pro-
teins was found in inferior parietal lobule and hippocampus of individ-
uals with AD and mild cognitive impairment compared with healthy
controls, indicating that oxidative-related impairment of components
of glucose metabolism might occur early in the development of AD
[53,60,95].
Mounting evidence supports the concept that AD is a metabolic dis-
ease in which brain glucose utilization and energy production are im-
paired. APP and Aβ have been shown to induce mitochondrial activity
defects and increased OS, and a number of studies on animal and cell
culture models of AD suggested that increased levels of OS are able to
impair key players of the glucose metabolic pathway [42,46,96]. In par-
allel, insulin-signaling impairment contributes to AD development by
favoring tau hyperphosphorylation, accumulation of Aβ, increased OS
and oxidative damage and mitochondrial dysfunction (Fig. 1). In this
regard, the analysis of oxidation and damage of protein belonging to
metabolic pathways (glucose metabolism) might be of interest in un-
derstanding the potential molecular mechanisms targeted by OS that
trigger common features between T2DM and AD. Redox proteomics
studies on AD brain demonstrated the oxidation of alpha-enolase
(ENO1), malate dehydrogenase (MDH), fructose bisphosphate aldolase
A/C (FBAA/C), ATP synthase, and glyceraldehyde 3-phosphate dehydro-
genase (GAPDH). Similarly, pyruvate kinase (PK), MDH, ENO1, FBA C,
and TPIwere found increasingly oxidized in amnesticmild cognitive im-
pairment (MCI) and preclinical AD (PCAD) brain [50,97–102].
Interestingly, redox proteomics data relate with PET studies that
demonstrated a reduction of the cerebral metabolic rate of glucose in
AD [103] and suggest that the oxidative damage of protein involved in
glycolysis, the Krebs cycle and ATP synthesis might be a crucial event
in the reduction of glucose metabolism (Fig. 1). In addition, the oxida-
tion of the above described proteins, culminatingwith reduced ATP pro-
duction, likely contributes to the loss of synapses and synaptic function
at nerve terminals merely leading to neurodegenerative processes and
cognitive decline (Fig. 1) [102,104]. Since this phenomenon appears
early in PCAD and MCI, it conceivably might be the consequence of
increased OS caused by insulin resistance, contributing to further alter-
ations of mitochondrial functionality that exacerbate even more
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onset of symptoms in AD and that oxidative damage is found before ro-
bust Aβ plaque formation, supporting a causative role of mitochondrial
dysfunction and OS in AD [42,46,105]. Within this context, data
supporting protein oxidation in the presence of insulin resistance and
reduced glucose utilization suggest the potential presence of a vicious
cycle among these events that eventually culminate with AD pathology
(Fig. 1). Consistent with this notion, studies on T2DM subjects demon-
strated increased levels of PCO AOPPs, AGEs, oxLDL, 8-OHdG, MDA,
NOx, and insulin resistance compared with control together with a sig-
niﬁcant drop in plasma \SH groups, free radical scavenging capacity
and deﬁcits in the antioxidant defense enzymes and vitamins
[106–110]. Moreover, the plasma GSH/GSSG ratio showed a signiﬁcant
decrease in T2DM as compared to healthy subjects, associated with in-
creased pentosidine, F2-isoprostanes, and HNE levels [111]. In this sce-
nario, OS represents undoubtedly a crucial event in the development of
T2DM and AD even if the exact role played by its aberrant increase has
not been clariﬁed. However, since OS is shared by both pathologies it
might represent the point of intersection between them. The potential
oxidative link between diabetes and AD is also supported by studies
on DS subjects, which demonstrate reduced glucose utilization, mito-
chondrial deﬁcit and increased OS early in life that might contribute to
the oxidation of metabolic enzymes, such as PK, ENO1, GAPDH and
FBA A/C, the build-up of insulin resistance, through the inhibition of
IRS1, and the progression to AD-like dementia [84,112,113].
3.1.2. The antioxidant response: the role of the heme-oxygenase and its by-
products
The heme oxygenase/biliverdin reductase (HO/BVR) system is one
of the main and evolutionarily conserved cellular cytoprotectants,
whose up-regulation represents an early event in the adaptive response
to stress [114]. Despite that the initial attention by the scientiﬁc com-
munity was focused primarily on the ability of this system to degrade
heme to be the main, if not the only, function, quite recently numerous
different functions have been elucidated. Humans and rodents have two
HO isozymes, namely HO-1 (about 32 kDa, enzyme) and HO-2
(36 kDa). Heme oxygenase-1, also known as heat shock protein
(Hsp)-32, is induced by various stimuli, including oxidative and
nitrosative stress, ischemia, heat shock, bacterial lipopolysaccharide
(LPS), hemin, the neuroprotective agent leteprinim potassium
(Neotroﬁn) [115,116] and several drugs currently used in the clinic,
such as statins, non-steroidal anti-inﬂammatory drugs, antagonists to
the adrenergic β receptor, and cyclosporine A [117,118]. Heme
oxygenase-2, the constitutive isoform, is responsive to developmental
factors, adrenal glucocorticoids, nitric oxide (NO) [115], atorvastatin
[118] and drugs acting on the nervous system, such as morphine and
glucocorticoids [117].
HO-1 and HO-2 catalyze the same reaction, namely the transforma-
tion of iron-protoporphyrin-IX-alpha (heme) into equimolar amount of
ferrous iron [Fe(II)], carbon monoxide (CO), and biliverdin-IX-alpha
(BV-alpha) [115,116]. Both the HO iso-enzymes and their by-products
were reported to play a role in the insulin signaling, shedding light on
the impairment of the antioxidant response as a central event in the de-
velopment of the insulin resistance.
First of all, previous studies demonstrated that HO-1 and HO-2
are not highly protective in AD brain due to their oxidative post-
translational modiﬁcations, which affect their levels and activities. In-
deed HO-2 protein levels were found signiﬁcantly decreased in AD
brain [119]. Conversely, because HO-1 is a stress-inducible protein, the
increase of OS levels in the hippocampus of AD subjects could lead to
an increase in HO-1 protein levels and phosphorylation in order to pro-
mote its activity and its interaction with BVR [120]. At the same time,
the increased OS could be responsible for the observed increased PC
modiﬁcations and HNE adducts, already demonstrated for other
proteins in AD [121] leading to altered protein structure and
function impairment [49,122–124]. Based on our experimental model(full homogenate of human brain samples), it is difﬁcult to state
which post-translational modiﬁcation precedes the other between
phosphorylation and oxidative modiﬁcation. At least two interpreta-
tions are conceivable: 1) OS promotes the increase of oxidative damage
to HO-1 (e.g., increased PC and HNE adducts on its structure). Conse-
quently, the cell tries to restore the functionality of the protein by in-
creasing Ser residue phosphorylation; and 2) OS promotes the
increase of Ser-residue phosphorylation in order to activate protein
functions, but HO-1 quickly becomes a target for oxidative post-
translational modiﬁcations, that, in turn, could impair its function
[119]. Considering that AD brain is characterized by abnormal levels of
oxidative and nitrosative stress [49], it is evident that the functionality
of the HO enzymes is compromised, and even in the case that the ﬁrst
interpretation was true, the restoration likely would only be partial,
and maybe not enough to promote neuroprotection [125].
With regard to diabetes, no data exist so far about the expression
levels and activity of HO in the human brain. The few lines of
evidence in mice show that HO-1 protein levels are increased in the
brain of db/db mice and that this increase parallels the augmentation
of isoprostanes and 8-OHdG, markers of lipid peroxidation and DNA ox-
idation, respectively [126]. Similarly, it was observed that the ferric
nitrilotriacetate (Fe-NTA)-induced diabetes in rats was associated
with an increase of HO-1 protein levels in the brain [127]. In addition,
in another work, HO-1 mRNA expression in the brain of diabetic rats
was unchanged with respect to the controls [128], thus leaving the in-
formation about HO-1 in the brain quite vague. Based on these data
and our experience, it becomes difﬁcult to argue a unique hypothesis
about the role of HO-1 in insulin resistance in the brain because what
is still missing with regard to diabetes is the data about HO activity
and/or post-translational modiﬁcations.
However, considerable information about a possible involvement of
HO in insulin resistance could come fromHO-derived by-products such
as ferrous iron and CO. Accumulating evidence suggests that iron (II)
plays a pathogenic role in T2DMand its complications, such asmicroan-
giopathy and atherosclerosis [129,130]. In addition to the induction of
OS, iron (II) may also impede insulin extraction in the liver, impair pan-
creatic insulin secretion, and interfere with insulin action and glucose
uptake in adipocytes. Of note, a reduction in iron overload with either
phlebotomy or iron chelation therapy has been shown to reverse or im-
prove glycemic control in T2DM [130]. Consistent with the above-
mentioned data, ferric nitrilotriacetate (Fe-NTA)-induced diabetes in
rats leads to increased ferrous iron in the cortex and hypothalamus, to-
gether with increased HNE [127], thus suggesting that increased HO ac-
tivity could impact iron production and thus OS-mediated insulin
resistance.
With regard to AD, the role of iron in the brain is clearer. Indeed, it
was demonstrated that redox-active iron is associated with senile
plaques and neuroﬁbrillary tangles, indicating that iron accumulation
could be an important contributor toward the oxidative damage of AD
[131], thus providing a basis for the future involvement of HO-1 as
one of the main source of iron deposition and accumulation. Further-
more, heme-derived ferrous iron may mediate the oxidative modiﬁca-
tion of mitochondrial lipids, proteins and nucleic acids in these cells.
Glial HO-1 hyperactivity may contribute to cellular OS, pathological
iron deposition, and bioenergetic failure characteristic of degenerating
inﬂamed neural tissues as observed in AD [132]. The same group dem-
onstrated that immunoreactive astocytic HO-1 proteinwas signiﬁcantly
increased in temporal lobe and hippocampal in subjects with MCI and
AD, and was associated with global measures of cognitive impairment
and speciﬁcmemory deﬁcits in these individuals. The authors suggested
a mechanism favoring early mobilization of free iron, mitochondrial in-
sufﬁciency and corpora amylacea formation in this neurodegenerative
disorder [133].
Experimental studies have indicated that iron deﬁciency is related to
increased insulin sensitivity in animals [134,135],while epidemiological
studies have reported an association between iron overload and
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intriguing because one can hypothesize that the deregulation of iron
mobilization and metabolism in AD brain may be responsible, at least
in part, for the observed insulin resistance. Thus, in accordance with
the hypothesis provided by our group [125], AD progression could be
associated with an initial over-activation of the HO-1 with the aim of
overcoming the raise of the OS levels. Then, the over-production of fer-
rous iron could participate in the impairment of insulin signaling both
directly [134,135] or indirectly by promoting a further increased OS
[41,137].
To support the idea that the impairment of the HO activity could
contribute insulin resistance observed in AD brain, the role of CO has
to be analyzed. Under normal physiological conditions, islets of
Langerhans produce CO and nitric oxide (NO) to regulate insulin release
[138,139]. While NO negatively modulates glucose-stimulated insulin
release, CO stimulates insulin secretion [138,139]. Moreover, glucose
stimulates pancreatic β-cells to produce CO, which in turn triggers insu-
lin release [138,139]. The critical role of the HO system in insulin release
and glucose metabolism was reported in Goto–Kakizaki (GK) rats, a
modelwith defective pancreatic β-cell HO-2 [140]. Since HO-2 is largely
responsible for basal HO activity [125] and thus the production CO, the
impairment of the HO system in GK rats resulted in reduced CO and in-
sulin insufﬁciency [140]. Treatment with the HO-inducer, hemin, or CO
corrected the defective HO system and enhanced insulin release with
improvement of glucose metabolism [140]. Collectively, these studies
suggest that reduced CO and/or impaired HO system may lead to dys-
functional glucose metabolism.
Whether CO also exerts these same effects in the brain is not well
established and needs further investigation. However, it is conceivable
to suppose that, due to the similarity between (i) peripheral insulin re-
sistance observed in T2DM, and (ii) brain insulin resistance as observed
in AD, CO could promote the same outcomes. For this reason, the ob-
served decrease of HO-2 and the impairment of HO-1 in AD [119,125]
acquire a new signiﬁcance in the ﬁeld of insulin resistance. Given the
above-mentioned data, we speculate the possibility that the elevation
of HO-1 in AD brain leads to an over-production of both ferrous iron
[131–133] and CO [125,141]. However, with the progression of AD pa-
thology, the impairment of HO-1 and the observed dysregulation of
the machinery involved in iron metabolism [142] result in the accumu-
lation of ferrous iron together with a decrease of CO levels, which
strongly affect insulin signaling. Indeed, the post-mortem analyses
showing in human AD brain both insulin resistance and reduced levels
of insulin, agree with the paradigm for which iron promotes insulin re-
sistance and CO promotes insulin secretion.
4. Oxidative stress and insulin resistance: therapeutic approaches
As described in more details below, several therapeutic approaches
aimed to counteract/slow the effects produced by insulin resistance in
AD pathology were recently identiﬁed. However, anti-diabetic drugs
such as metformin, sulfonylureas, and thiazolidinediones (rosiglitazone
and pioglitazone) failed to reduce the risk of developing AD or restoring
the observed impairment in learning and cognition probably because of
their: (i) rapid degradation; (ii) poor penetrance of the BBB; and (iii) in-
ability to reduce insulin resistance in vivo. On the other hand, intranasal
insulin administrationwas able to improve delaymemory recall associ-
ated with changed CSF Aβ42 levels and tau protein-to-Aβ42 ratios
[143]. Because a wide literature already has focused on the pro and
cons of these drugs, we provide here an analysis of the effects that
these drugs have on OS, when known.
4.1. Metformin
Metformin belongs to the class of biguanides, which are agents able
to reduce hepatic glucose output and increase uptake of glucose in the
periphery, including skeletal muscle. Although it must be used withcaution in patients with impaired liver or kidney function, metformin
has become the most commonly used agent for type 2 diabetes, and it
is the only widely used oral drug that does not cause weight gain
[144]. Themolecularmechanism ofmetformin is not completely under-
stood: inhibition of themitochondrial respiratory chain (complex I), ac-
tivation of AMP-activated protein kinase (AMPK) and the consequent
inhibition of mTOR activity, inhibition of glucagon-induced elevation
of cyclic adenosine monophosphate (cAMP) and consequent activation
of protein kinase A (PKA), and an effect on gut microbiota have been
proposed as potential mechanisms [145,146].
In 2009, it was shown that metformin signiﬁcantly increased the
generation of the intracellular and extracellular Aβ species both
in vitro (10 mM, N2a695 cells) and in vivo (2 mg/mL per os, C57B6
mice) through the up-regulation of β-secretase (BACE1), which results
in an elevated protein level and increased enzymatic activity [147]. In
addition, the surface levels of LRP1 (low-density lipoprotein receptor-
related protein 1), noted above to be a major efﬂux transporter for
brain Aβ1–42 and found to be oxidatively modiﬁed in AD brain [123],
were decreased after metformin treatment [147]. Later, other studies
showed that metformin induces PP2A activity and reduces tau phos-
phorylation at PP2A-dependent epitopes in vitro (2.5 mM, different
cell types) and in vivo (5 mg/mL per os, WT mice) [148]. Treatment
withmetformin (1.6 mM, N2A cells) sensitized impaired insulin actions
and also prevented the appearance of molecular and pathological char-
acteristics observed in AD such as tau phosphorylation, GSK-3β activa-
tion, increased Aβ1–42 production and diminution of acetylcholine
esterase activity [149]. In 2012, the ﬁrst pre-clinical study aimed to
study the effects of metformin (200 mg/kg/d, IP) administered to dia-
betic animals (db/dbmice) for a long-time (18 weeks) on AD-like bio-
chemical and cognitive changes in brain was performed. Metformin
reportedly attenuated the increase of total tau, phospho-tau and acti-
vated c-jun N-terminal kinase (JNK) as well as Aβ levels in the hippo-
campus, in agreement with previous ﬁndings [147,149]. Despite these
changes, metformin did not attenuate the impairments of spatial learn-
ing andmemory [150]. In another study, high fat-fed animals developed
insulin resistance and an impairment in switching task contingency
from a matching to a non-matching paradigm, highlighting impaired
cognition. Metformin (144 mg/kg in diet for 10 weeks) attenuated in-
sulin resistance and weight gain associated with high-fat feeding, but
had no effect on cognitive performance. In addition, no major alter-
ations in proteins associated with insulin signaling or synaptic function,
were detected [151]. Unfortunately, the above-cited studies did not
evaluate OS levels, given the observed metformin-induced improve-
ment of the AD-like changes suggested a possible positive impact also
on the OS levels. Indeed, a signiﬁcant decrease in TBARS andMDA levels
as well as glutathione peroxidase (GPx) activity together with a signiﬁ-
cant increase in GSH levels andMnSOD activity was observed in GK rats
(amodel of diabetes) treatedwithmetformin for 4 weeks. These results
suggest that metformin protects against diabetes-associated OS imply-
ing that metformin might be an effective neuroprotective agent [152].
Similarly, in high fat-diet fed rats, metformin (15 mg/kg BW twice
daily, for 21 days) signiﬁcantly attenuated the insulin resistant condi-
tion by improving metabolic parameters, decreasing peripheral and
brain OS levels, and improving learning behavior, compared to the
vehicle-treated group [153]. Furthermore, metformin completely
prevented brain mitochondrial dysfunction caused by long-term high
fat-diet consumption [153]. In another study, chronic metformin ad-
ministration preventedmemory impairment induced by administration
of L-methionine and these changeswere associatedwith a restoration of
the antioxidant defenses (signiﬁcant decrease in GSSG and TBARs, along
with elevation in GSH/GSSG ratio and activities of catalase and GPx)
[154]. In light of these results, it clearly appears that both dose and
time-of-treatment have to be carefully analyzed in order to understand
the therapeutic window giving better outcomes. However, with regard
to the translation from animals to human, in 2012 and 2013, two
population-based case–control studies reported a higher risk of AD in
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effective protective role for this drug. Consequently, both pre-clinical
and clinical of metformin suggest that further investigations are neces-
sary to fully determine whether thus mTOR inhibition has promise in
treatment AD patients with diabetes.
4.2. Sulfonylureas
Sulphonylureas lower blood glucose by inhibiting the KATP channel
of the pancreatic beta cells and thus stimulating insulin secretion and
its levels in the blood [157]. Glibenclamide (0.3 mg/kg per os, for
3 weeks) reduced hyper-phosphorylated tau protein levels in i.c.v.-Aβ
administered rats [158]. Furthermore, glibenclamide (1 mg/kg, i.p.) de-
creased lipid peroxidation and myeloperoxidase activity accompanied
by increased glutathione levels and total antioxidant capacity in the hip-
pocampus of rats that had undergone ischemic-reperfusion injury,
highlighting a potential therapeutic utility for this sulfonylurea in
brain injury via modulating OS and inﬂammatory mediators [159]. In
another study, gliclazide (10 mg/kg, for 21 days) decreased the total
oxidant index and increased the total antioxidant defense in the brain
of diabetic rats, thus shifting the oxidant/antioxidant balance toward
the antioxidant status. This study was the ﬁrst experimental research
demonstrating the effectiveness of gliclazide to protect diabetes-
induced OS in the brain of diabetic rats [160]. In contrast to metformin,
long-termuse of sulfonylureaswas not associatedwith an altered risk of
developing AD in humans [155].
4.3. Thiazolidinediones
Thiazolidinediones (TZDs) are currently among the two classes of
oral hypoglycemic agents – the other is the class of biguanides – that
serve as insulin-sensitizers for the treatment of T2DM.While the precise
mechanism of action for the broad metabolic effects of TZDs remains
unclear, there is a consensus that TZDs depend upon the activation of
peroxisomal proliferator-activated receptor gamma (PPARγ) nuclear
receptors that aremost abundant in adipose tissues but are also present
in liver, macrophages and other immune cells, pancreatic beta-cells,
bone, and many other tissues [161].
In 2000, it was reported that troglitazone (20–50 μM) prevented
both the activation of microglia and the expression of the IL-6, TNF-
alpha and those of cycloxygenase-2 following Aβ-stimulated proinﬂam-
matory response, thereby attenuating the activation of both microglia
and astrocytes and the consequent elaboration of neurotoxins [162].
Notwithstanding that troglitazone was withdrawn due to hepatitis
and liver damage risk, this drug represented the ﬁrst study about the
possible neuroprotective role of thiazolidinediones.
With regard to the two most prescribed thiazolidinediones,
pioglitazone and rosiglitazone, data available in literature are not
completely consistent between pre-clinical and clinical outcomes,
mainly due to differences in doses and time of the treatment. Pioglita-
zone (20 mg/kg/d, for 16 weeks) only modestly reduced SDS-soluble
Aβ levels and did not affect amyloid plaque burden or microglia activa-
tion in 11-month old Tg2576 mice, suggesting that PPARγ activation
does not greatly affect Aβ levels [163]. Similarly, in a murine model of
AD, pioglitazone (120 mg/g/d, for 2 months) decreased cerebral glu-
cose utilization, thus suggesting that it does not act as a metabolic en-
hancer in AD [164], but rather, it would increase neurotoxicity in the
brain, maybe due, at least in part, to a glucose-dependent generation
of ROS [39,165]. Other studies, in contrast, reportedmajor neuroprotec-
tive effects following pioglitazone administration, mainly based on re-
duced glial activation coupled with Aβ reduction-associated cognitive
improvement. In transgenic APP mice, pioglitazone (20 mg/kg/d, for
4 weeks) fully restored cerebrovascular reactivity of isolated cerebral
arteries concomitantly with changes in proteins regulating OS, without
reducing brain Aβ levels or plaque load [166]. Indeed, pioglitazone sig-
niﬁcantly attenuated astroglial activation and improved, albeit notsigniﬁcantly, reduced cortical cholinergic innervation [166]. In addition,
pioglitazone completely normalized cerebral blood ﬂow and the
cerebral glucose utilization responses to increased neuronal activity,
but it failed to improve spatial memory [166]. These results were the
ﬁrst to demonstrate that late pharmacological interventionwith pioglit-
azone not only overcomes cerebrovascular dysfunction and altered
neurometabolic coupling in aged APP mice, but also counteracts cere-
bral OS, glial activation, and, partly, cholinergic denervation [166]. Con-
versely, in 10-month-old APPV717I transgenic mice that received an
oral treatment with either standard chow or chow containing pioglita-
zone (40 mg/kg/d, for 7 days), this latter not only reduced glial activa-
tion and BACE1 protein levels, but also Aβ42-positive amyloid deposits
and their respective staining intensity aswell as soluble Aβ42 in the hip-
pocampus and frontal cortex [167]. Because only ∼18% of orally admin-
istered pioglitazone crosses the intact blood–brain barrier in mammals
[168], it seems likely that drug dosage, rather than treatment duration,
is critical to observe drug effects in the brain. Recently, pioglitazone
both in APP/PS1 mice (80 mg/kg/d, for 9 days) and in the triple trans-
genic mouse model of AD with accelerated amyloid-β (Aβ) deposition
and tau pathology (3xTg-AD, 18 mg/kg/d, for 4 months), promoted
multiple beneﬁcial effects, including improved learning, reduced
serum cholesterol, decreased hippocampal amyloid-β and tau deposits,
and enhanced short- and long-term plasticity [169,170]. Furthermore,
pioglitazone (20 and 40 mg/kg, i.p., for 21 days), showed signiﬁcant
dose-dependent improvement in scopolamine-induced dysfunctions
in long-term and visuo-spatialmemory in passive avoidance andMorris
water maze tests, respectively [171]. The same treatment signiﬁcantly
prevented the fall in GSH levels and elevation in brain MDA levels
induced by scopolamine. These results demonstrate that pioglitazone
offers protection against scopolamine-induced dysfunctions in long-
term and visuo-spatial memory, possibly due to its antioxidant action,
and potentially could have a therapeutic utility in AD [171].
Reduction of theOS levelswas also reported in the hippocampus and
cerebral cortex of fructose-drinking insulin resistance rats in which a
signiﬁcant decrease of ROS, TBARS and protein carbonyls levels together
with an increase of both GSH levels and SOD, CAT and GPx activities,
was observed following pioglitazone administration (10 mg/kg, for
12 weeks) [172]. Decreased OS levels were paralleled by a partial im-
provement of the cognitive impairment, suggesting that the neuropro-
tective effects mediated by this drug can be due, at least in part, to an
improvement of antioxidant defenses [172]. Consistentwith this notion,
pioglitazone (20 mg/kg/d) inhibited iron-induced α-synuclein aggre-
gation, elevation in interleukin-1β and interleukin-6 mRNA levels as
well as increases in HO-1, COX-2, NOS and ED-1 protein levels, indica-
tors of activated microglia. Moreover, iron-induced DNA laddering as
well as activation of ER and mitochondrial pathways were attenuated.
In addition, pioglitazone decreased iron-induced elevation in lipid per-
oxidation in the substantia nigra. Due to the reasons discussed in the
previous section, these results emphasize the importance that iron me-
tabolism and HO-1 activity dysregulation have in AD pathology and
suggest that pioglitazonemay be a novel therapeutic approach to inves-
tigate with regard to its effects on iron and HO-1.
Studies in humans reported an overall improvement of cognitive
function, whose related molecular mechanism in the brain are not
knownbecause of the lack of biochemical analyses. Indeed, in a prospec-
tive randomized, open-controlled study, MCI and AD patients treated
with pioglitazone (15–30 mg/d, for 6 months) showed signiﬁcantly de-
creased ADAS-Jcog scores and increased WMS-R logical memory-I
scores, thus suggesting an improvement in cognitive function [173]. In
another study, AD patients also diagnosed with T2DM treated with pio-
glitazone (15–30 mg/d, for 6 months) showed improved cognition to-
gether with an increase of the plasma Aβ40/Aβ42 ratio, and a decrease
in fasting plasma insulin levels, this latter parameter indicating en-
hanced insulin sensitivity [174].
With regard to rosiglitazone, an attenuation of progression of insulin
resistance in Tg2576 mice with age to the rate occurring in wild-type
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ed [175]. In the same animal model, rosiglitazone administration
(30 mg/kg/d for 7 months) fostered better spatial learning andmemory
abilities together with a reduction in: (i) insulin-degrading enzyme
(IDE) mRNA and activity; and (ii) Aβ42 levels without affecting amyloid
deposition in the brain [176]. The beneﬁcial effects on learning and
memory were also observed in another model of AD, the transgenic
hAPPSwe-Ind, in which rosiglitazone (5 mg/kg/d, for 10 weeks) reversed
memory decline along with an increased expression of the glucocorti-
coid receptor in the hippocampus [177]. The normalization of glucocor-
ticoid receptors levels by rosiglitazone may contribute to the beneﬁcial
effect on cognition of this potent PPARγ agonist by restoring the physi-
ological control of the HPA axis. In the same transgenic hAPPSwe-Ind an-
imal model, rosiglitazone (5 mg/kg/d, for 4 months) ameliorated
memory deﬁcits, promoted glial activation, and reduced brain Aβ levels,
plaque deposition and p-tau aggregates [178]. The observed reduction
in amyloid and tau pathology after rosiglitazone could be because of
an increase in the brain clearance ability, consistent with a positive ef-
fect also on OS markers [178]. Reduction of Aβ levels was also observed
in APP/PS1 mice that underwent rosiglitazone treatment (6 mg/kg/d,
for 4 weeks) [179]. In contrast to pioglitazone, rosiglitazone induced
neuronal mitochondrial biogenesis and improved glucose utilization
leading to improved cellular function [180]. However, results in animals
do not completely parallel with clinical observations, in particular
for cognitive improvement. In a placebo-controlled, double-blind,
parallel-group pilot study, subjects receiving rosiglitazone (4 mg/d for
6 months) exhibited better delayed recall and selective attention
[181]. Conversely, exploratory analyses in humans suggested that 2, 4
and 8mg daily had no statistically signiﬁcant treatment effect on cogni-
tion as measured by ADAS-Cog. However, APOE epsilon4 non-carriers
exhibited cognitive and functional improvement in response to
rosiglitazone, whereas APOE epsilon4 allele carriers showed no im-
provement and some decline was noted [182]. In a double-blind, ran-
domized, placebo-controlled study, rosiglitazone mono-therapy
(2–8 mg/d, for 24 weeks) did not show any improvement in cognition
or global functions inmild-to-moderate AD patients [183]. Consequent-
ly the utility of TDZs for treatment of AD remains to be proven.
4.4. Insulin
Insulin is a peptide hormoneproduced byβ cells in the pancreas that
is central for regulation of carbohydrate and fat metabolism as well as
body weight and food intake. However, as cited above, insulin is also
produced directly in the brain, thus opening questions about its physio-
logical relevance. Indeed, the role of insulin signaling in the regulation of
learning, and memory formation in the human and rodent brain is a
matter of controversy. The conﬂicting information on insulin action in
the CNS arises from difﬁculties in dissecting the direct actions of insulin
in the brain from the effects resulting from hypoglycemia after periph-
eral administration of insulin [34]. Given that IRs are widely expressed
in the hippocampus, the most important brain region for learning and
memory, it is plausible that decline of IR signaling leads to cognitive im-
pairment [184,185]. Importantly, high levels of markers of insulin resis-
tance were associated with poor performance on tests of working and
episodic memory, independent of levels of β-amyloid and neuroﬁbril-
lary tangles, suggesting that insulin signaling has a direct effect on cog-
nitive status. This observation may help to explain the ﬁnding that
adults with either amnestic MCI or non-amnestic MCI (the latter
group being presumed not to have prodromal AD) showed increased
basal levels of IRS-1 serine kinases [143]. Based on the observation of
defective insulin signaling in the brain, it was proposed that insulin
treatment could rescue insulin resistance and improve cognitive func-
tion. Among the possible mechanisms involved in the neuroprotective
effects of insulin, decreasing OS levels received great attention. A num-
ber of studies highlighted this aspect and for this reason we will limit
our analysis to the major achievements obtained with regard to AD. In2005 Moreira et al. showed that in the brain of streptozotocin (STZ)-
treated rats, insulin (5–20 UN/kg, for 4 weeks) prevented the decline
in mitochondrial oxidative phosphorylation efﬁciency and prevented
increased OS, improving or preserving the function of neurons under
adverse conditions, such as AD [186]. In addition, insulin (0.1 and 10
μM) prevented the decrease in neuronal viability mediated by OS, de-
creasing both necrotic and apoptotic cell death [187]. Indeed, insulin
inhibited ascorbate/Fe2+-mediated lipid and protein oxidation as well
as decline of the GSH/GSSG levels. Interestingly, increased HNE adducts
on GLUT3 glucose transporters upon exposure to ascorbate/Fe2+ were
also prevented by insulin, suggesting that this peptide can interfere
with glucose metabolism. Inhibition of PI3K or MEK reversed the effect
of insulin on the GSH/GSSG ratio, suggesting the activation of insulin-
mediated signaling pathways [187]. The same authors showed that in
rat primary cortical neurons insulin neuroprotection against OS-
mediated damage involves: 1) stimulation of glucose uptake and me-
tabolism, increasing energy levels and intracellular adenosine and,
ultimately, uric acid formation; and 2) a decrease in extracellular aden-
osine, whichmay reduce the facilitatory activity of adenosine receptors
[188]. Further, it was shown that insulin (0.1–10 μM) prevented OS-
induced increased GPx-1 and decreased hexokinase-II expression in
rat primary cortical neurons, supporting previous ﬁndings of changes
in glutathione redox cycle and glycolysis [189]. Moreover, insulin pre-
cluded Bcl-2 decreased expression and caspase-3 increased expression.
Consistent with these results, insulin abolished caspase-3 activity and
DNA fragmentation caused by OS [189]. Thus, insulin-mediated
activation of IR/IGF-1R stimulates PI3K/Akt and inhibits GSK-3beta sig-
naling pathways, modifying neuronal antioxidant defense-, glucose
metabolism- and anti-apoptotic-associated protein synthesis [189]. In
2009, De Felice et al. reported for the ﬁrst time that 100 nM insulin par-
tially prevented and 1 μM insulin completely blocked Aβ-derived
diffusible ligands-induced loss of dendritic IRs in hippocampal cultures
and IR accumulation in the cell body together with a reduction of neu-
ronal ROS [190].
In 2008, low doses of IGF-1 (2.25 μg/100 g/d, for 1 month) restored
circulating IGF-1, improved glucose and lipid metabolism, increased
testosterone levels and serum total antioxidant capability, and reduced
oxidative damage in brain and liver of aging rats together with a nor-
malization of antioxidant enzyme activities and mitochondrial function
[191,192], suggesting that not only insulin but also IGF-1 as therapeutic
targets to combat insulin resistance. With regard to themechanisms in-
volved in insulin/IGF-1-mediated neuroprotection, insight came from
transgenic mouse overexpressing IGF-1, which showed reduced levels
of oxidized proteins in the brain associated with an activation of the
proteasome via processes involving the PI3K/mTOR axis [193]. These
data suggest that appropriate levels of IGF-1 may be important for the
elimination of oxidized proteins in the brain in a process mediated by
activation of the proteasome and are consistent with ﬁndings by us
and others suggesting the inactivation of proteasome in AD [113,194].
However, despite amajority of results that suggested a neuroprotec-
tive role of insulin treatment, some reports highlighted insulin toxicity.
Indeed,while effectively attenuating neuronal apoptosis inmouse corti-
cal culture, insulin paradoxically induced neuronal necrosis with 48 h of
exposure, and these effects were blocked by an antioxidant [195]. Sim-
ilarly, insulin (10–100 ng/mL) could act as anti-apoptosis factor and
pro-oxidant depending upon the activation of PI3K in cortical neurons
[196]. In addition, ascorbate/Fe2+-induced increased TBARSs was simi-
lar in synaptosomal fractions obtained from the brain of Wistar and di-
abetic GK rats and was not reverted by insulin (1 μM), suggesting that
othermechanisms, rather than a direct effect onmembrane lipid perox-
idation may mediate insulin neuroprotection [197].
On the other hand, due to its strong effects on glucose uptake, insulin
could promote a drastic decrease in glucose levels, clearly not a desired
result. An intriguing study inmice reported that the severity of hypogly-
cemia induced by intraperitoneal administration of insulin at a dose
24 IU/kg was associated with the levels of MDA, CuZn-SOD and GPx
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concentration below 1.0 mM) the lipoperoxidation in brain tissue
expressed as the level of MDA was higher in comparison with
normoglycemic controls (glycemia around 3.7 mM) as well as in
comparison with the levels of MDA during moderate hypoglycemia
(glycemia ranging between 1 and 2 mM). This indicates the enhance-
ment of lipoperoxidation in the brain tissue during severe hypoglyce-
mia [198].
As enhanced brain insulin signaling improves memory processes
and possesses neuroprotective properties, increasing brain insulin con-
centrations in AD patients could be a promising approach to prevent or
slow the progression of this devastating disease. In order to avoid the
side effects associated with peripheral hypoglycemia, intranasal insulin
(INI) has been proposed as a safe treatment for neurodegenerative dis-
orders, including AD [199]. Mechanisms of INI for bypassing the BBB to
reach the brain have been reviewed [199]. INI reaches the CSF in 10min
without meaningful absorption into the circulation [200] and reaches
the brain in a fully functionally active condition [201]. Craft and co-
workers used INI in patients with amnestic MCI and AD to demonstrate
improved delay memory recall that was associated with changed CSF
Aβ42 levels and tau protein-to-Aβ42 ratios [143]. Compared to placebo
controls, INI-treated patients showed improved glucose utilization
based on F-18DG PET studies [143]. Whether the INI treatment that
was associatedwith positive effects on cognitive function alsowas asso-
ciated with a reduction of OS levels in the brain, is something not yet
established, and studies on this topic are currently ongoing in our
laboratory.
4.5. GLP-1 agonist and DPP-4 inhibitors
Glucagon-like peptide 1 (GLP-1) is an endogenous insulinotropic
hormone that has an important role in the balance between insulin
and glucose levels [202]. Indeed, GLP-1 is secreted by intestinal
endocrine L-cells in response to ingestion of nutrients, and among its
functions are as follows: (i) stimulates glucose-dependent insulin secre-
tion and insulin biosynthesis in the pancreatic beta-cells; (ii) inhibits
glucagon secretion in the pancreatic alpha-cells; and (iii) slows gastric
emptying thus prolonging satiety [202]. Interestingly, GLP-1 also is
expressed in neurons and acts as a neurotransmitter [203]. Building
on this background, GLP-1 mimetics have been developed as a treat-
ment for T2DM, but it became apparent that these drugs possess a num-
ber of other physiological properties such as neuroprotective and anti-
inﬂammatory effects, which may be useful to slow AD progression
[204]. Because GLP-1 is quickly metabolized by the activity of the
serine protease dipeptidyl peptidase 4 (DPP-4), which limits GLP-1
actions [205–208], synthetic GLP-1 analogs such as exendin-4,
liraglutide, and lixisenatidewere developed to be resistant to DPP-4. In-
deed, with regard to the anti-diabetic drugs previously discussed, GLP-1
agonists showed improved passage through the BBB similar to GLP-1
and a great ability to bind to the GLP-1R, thus promoting: (i) reduction
of insulin resistance; (ii) neuroprotective effects; (iii) activation
of neuronal stem cells; and (iv) improvement of cognitive functions
[209].
With regard to the effects on OS of GLP-1 or its analogs, only a few
results are available, mainly on the effects mediated by GLP-1 or
exedin-4. In 2003 it was reported that both GLP-1 and exedin-4 infused
ICV in the brain of db/dbmice [GLP-1 (3.3–6.6 ng) and exedin-4 (0.2 ng)
for 14d], or administered to primary cortical neurons [GLP-1 (1–20 nM)
and exedin-4 (50–500nM) for 2 h] reduced either sAPP or Aβ levels that
were correlated with a reduction of Aβ- or iron-induced OS-associated
cell death [210].
The neuroprotective effects of exedin-4 were also demonstrated in
both primary cortical neurons and SH-SY5Y cells in which exedin-4
(50–500 nM) ameliorated Aβ- and hydrogen peroxide-induced cell
death [211]. In another study, both GLP-1 (50–1000 nM) and exedin-4
(50–1000 nM) increased the viability of neuronal cells under eitherhigh glucose or oxidative stress conditions in vitro, and in vivo exedin-
4 treatment (10 μg/kg, ICV, for 14 d) led to improved memory and cog-
nitive performance in rats treated ICV with STZ [212].
Similarly, in vitro results showed that methylglyoxal (MG, 1 mM),
known to accumulate following excessive glucose levels and to be asso-
ciatedwith AD pathology, induced apoptosis in PC12 cells by promoting
the imbalance of GSH/GSSG ratio, whereas GLP-1 (0.33–3.30 μg/mL)
protected against this MG-induced apoptosis [213]. Indeed, GLP-1
promoted the phosphorylation of PI3K, Akt, and mTOR, as well
as the upregulation of GCLc and the restoration of the redox imbal-
ance [213]. Inhibitors of PI3K (LY294002), Akt (Akt-I), and mTOR
(rapamycin) reduced the GLP-1-induced GCLc upregulation and its pro-
tection against MG-induced PC12 apoptosis [213]. The GLP-1-induced
restoration of redox balance was also attenuated by rapamycin [213].
These results suggest that the neuroprotective effects of GLP-1 could
be associated with an enhancement of PI3K/Akt/mTOR/GCLc/redox
signaling.
Interestingly, geniposide (50 mg/L) – a GLP-1 agonist isolated from
the fruits of Gardenia jasminoides ELLIS (Rubiaceae) – increased the ex-
pression of anti-apoptotic proteins, including Bcl-2 and HO-1, to
antagonize the oxidative damage in PC12 cells induced by hydrogen
peroxide [214]. LY294002 (a PI3K inhibitor) inhibited the effect of
geniposide by activation of MAPK, MEK and c-Raf phosphorylation in
hydrogen peroxide treated PC12 cells [214]. U0126 (a selective inhibitor
of MEK) also attenuated the enhancement of geniposide on Bcl-2 levels
by inhibiting the phosphorylation of p90RSK in the hydrogen peroxide
treated PC12 cells [214]. All these data suggest that geniposide regulates
expression of anti-oxidative proteins including HO-1 and Bcl-2 by
activating the transcriptor of p90RSK via MAPK signaling pathway in
PC12 cells.
Lixisenatide, an effective GLP-1 receptor (GLP-1R) agonist with
much longer half life than GLP-1, has been licensed in the EU as a treat-
ment for T2DM. In 2014, Cai et al. reported for theﬁrst time the effects of
lixisenatide on Aβ-induced impairments in spatial learning and memo-
ry of rats, and investigated its electrophysiological andmolecularmech-
anisms [215]. These researchers found that lixisenatide (5 nmol/μL,
ICV) treatment: (i) effectively prevented Aβ(25–35)-induced cognitive
impairments; and (ii) inhibited Aβ(25–35) injection-induced ac-
tivation of GSK3β, with a signiﬁcant increase in the phosphorylation
of Ser9 and a signiﬁcant decrease in the phosphorylation of Tyr216
[215].
With regard to liraglutide, a number of studies reported that this
agent (25 nM, IP, administered with different schemes of treatment):
(i) reduced total APP and Aβ levels; (ii) reduced microglia activation;
(iii) increased neurogenesis; and (iv) improved cognitive function in
APP/PS1 mice [216–218].
Though direct information in the case of lixisenatide or liraglutide is
lacking, these results could well be consistent with a hypothesized re-
duction of OS in the brain of this AD-relevant mouse model. Further in-
vestigations are required to clarify this point.
Drugs able to inhibit DPP-4, such as sitagliptin, saxagliptin and
vildagliptin have been shown to possess neuroprotective effects against
AD-induced pathology, and studies on those molecules are ongoing.
DPP-4 inhibitors such as sitagliptin (Januvia) and sitagliptin in combina-
tion with metformin (Janumet) are approved in the USA for the treat-
ment of T2DM. Similarly, vildagliptin (Galvus), a potent and selective
DPP-4 inhibitor in combination with metformin or thiazolidinedione,
is approved by the European Union for the treatment of T2DM [219].
In 2010, the ﬁrst study on the role of DPP-4 inhibitor in AD from
D'Amico et al. showed that sitagliptin (5, 10 and 20 mg/kg, gastric
gavage, for 12w): (i) counteracted the memory impairment in a
contextual fear conditioning test; (ii) increased the brain levels of
GLP-1; (iii) produced signiﬁcant reductions of nitrosative stress and in-
ﬂammation hallmarks within the brain; and (iv) led to a signiﬁcant
diminution in the ultimate number and total area of βAPP and Aβ de-
posits in APP/PS1 mice [220].
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sal of cognitive deﬁcits that may be attributed to its unique mechanism
of lowering amyloid load, tau phosphorylation and inﬂammation in the
brain of STZ-induced AD rats, results consistent with the notion that
saxagliptin has neuroprotective properties [221]. In the same animal
model, vildagliptin (2.5, 5 and 10 mg/kg, for 30 d) promoted a time-
dependent improvement in memory retention and a dose-dependent
attenuation of Aβ, tau phosphorylation and inﬂammatory markers and
increased GLP-1 levels [222]. As some DPP-4 inhibitors are already in
the market for the treatment of T2DM, they are considered safe for
chronic use. However, further investigation is required to elucidate the
neurochemical and molecular mechanisms involved in the DPP-4-
induced neuroprotective effects.
Finally, because all of these results were obtained both in vitro and
in vivo pre-clinical studies, it might be interesting to go further with
RCTs in order to determinewhether such GLP-1mimetic- and DPP-4 in-
hibitor-associated effects are applicable in humans. In that regard it
would be helpful to keep in mind the results obtained in Parkinson dis-
ease that showed that, in the ﬁrst clinical trial designed to analyze the
effects of exedin-4 in human brain, exenatide-4-treated patients had a
mean improvement at 12 months on the Movement Disorders Society
Uniﬁed Parkinson's Disease Rating Scale (MDS-UPDRS) of 2.7 points,
compared with mean decline of 2.2 points in control patients [223]
and that these motor and cognitive advantages persisted 12 months
after exenatide exposure [224] (Table 1).Table 1
Main outcomes obtained in both pre-clinical and clinical studies by using anti-diabetic drugs t

















Epidemiological studies evince a strong link between T2DM and risk
of developingAD. The precisemechanismbywhich this enhanced risk is
conferred remains unclear, butmay coalesce around the elevated oxida-
tive stress in both T2DMand AD. The roles of radical damage to key pro-
teins in the insulin signalingpathways and to other key proteins in brain
may contribute to the elevated risk of T2DM patients developing AD.
More research into these topics is warranted given the explosive in-
crease in T2DM in Western cultures, even among younger individuals.
Therapies for T2DMoften appear to be beneﬁcial in animalmodels of
diabetes, but do not seem to translate into human trials of AD patients,
with perhaps one exception: intranasal insulin. It is our view that fur-
ther work into INI treatment to prevent or slow progression of amnestic
MCI is needed and important to pursue. The role of oxidative stress and
its modulation by INI in unique mouse models of AD and T2DM are
being investigated in our laboratory.Acknowledgements
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Main outcomes in AD
• Increases or prevents Aβ levels (discordant results)
• Increases β-secretase levels and activity
• Decreases LRP-1 levels
• Reduces tau phosphorylation
• Prevents GSK-3β activation
• Promotes acetylcholine esterase activity
• Decreases OS
• Increases GSH levels and MnSOD activity
• Reduces tau phosphorylation
• Reduces lipid peroxidation
• Increases antioxidant defense
• Improves cognition
• Prevents the activation of microglia
• Prevents the expression of the IL-6, TNF-alpha and cycloxygenase-2
• Decreases cerebral glucose utilization and increase ROS production
• Reduces Aβ levels
• Reduces β-secretase levels
• Decreases OS markers
• Reduces iron-induced increase of HO-1, COX-2, NOS and ED-1 protein levels
• Improves or worse cognition (discordant results)
• Decreases OS markers
• Improves neuronal functions
• Prevents OS-induced neuronal death
• Decreases necrotic and apoptotic cell death
• Precludes Bcl-2 decreased expression and caspase-3 increased expression
• Stimulates PI3K/Akt pathway
• Inhibits GSK-3β
• Promotes an improvement of cognitive functions associated with changes of
CSF Aβ42 levels and tau protein-to-Aβ42 ratios
• Improve cognition
• Reduce either APP or Aβ levels
• Reduce Aβ- or iron-induced OS-associated cell death
• Increase neuronal viability
• Promote the activation of the PI3K/Akt/mTOR axis
• Increase Bcl-2 and HO-1 protein levels
• Reduce Aβ25-35-induced activation of GSK3β
• Increase neurogenesis
• Improve cognition
• Increase GLP-1 levels
• Reduce nitrosative stress
• Reduce βAPP and Aβ deposits
• Reduce tau phosphorylation
• Improve cognitive functions
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